The Fund Grade · free · no account needed
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Sands Capital Global Growth Fund Investor Shares
#97 of 500 graded active funds · growth · large segment peer group
The point · specialist footprint
SCGVX puts more of its book behind proven specialists than 85% of graded funds.
Bottom 20%
Bottom 40%
Middle
Top 40%
● Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8% per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
10,000+ funds tracked · the graded specialists among them drive every read
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
SCGVX vs the Honor Roll · share card ↗Conviction exposure
51.7%
of the book in specialist-converged names
Late-stage weight
19.2%
of the book in Crowded or Fading names
Active share
91%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
SCGVX earns a B grade and ranks 97 out of 500 graded funds, with specialists holding a meaningful 51.7% share. The early story here is NVDA at nearly 10% of the portfolio, alongside AMZN and Bloom Energy, all at the Early Conviction stage. The concern is a cluster of Crowded or Fading names including GOOGL, ASML, and NFLX totaling over 17% of the fund.
→ Watch the ASML position closely, as specialists are actively leaving a name that still holds 4.3% weight.
→ Consider whether the GOOGL, NFLX, and MELI crowding risk offsets the genuine early upside in NVDA and BE.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.